Ionis Pharmaceuticals has signed the rights to a second antisense drug over to Janssen for a fee of $5 million.

A Yale team has developed an alternative gene-editing technology that they say replaces CRISPR’s “hacksaw” effect with a more precise “scalpel.”

A protein that senses and responds to high cholesterol could serve as a new target for drug development.

In this week's EuroBiotech Report, Bayer spends big on Loxo drugs, CureVac lands Cas9 deal, Gates invests in Alzheimer’s and more. 

Cancer and autoimmune startup Cue Biopharma has ended the year with a potentially lucrative new deal with Merck.

Evelo Biosciences has just forged closer ties with a heavyweight academic partner for its monoclonal microbials R&D, which envisages using bacteria to…

Bay Area drug discovery company Verge Genomics has formed industry and academic alliances in neuro disorders.

The gene silencing pioneer expects to complete the submission by the end of the year, setting it up to win approval in the U.S. in 2018.

The series B equips X4 to move deeper into the clinic on two fronts, with phase 2 and 3 trials in cancers and rare diseases on the horizon.